Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Edwards Lifesciences Corporation. A complete text table follows the diagram.
TAVR remains the profit engine, while mitral and tricuspid therapies scale twice as fast internationally as the established U.S. franchise
Swipe to explore
Product and geography are two separately reported views of the same revenue pool and do not imply product-level geography. Commercial and other operating cost is the exact net of $522.2M SG&A, $37.1M litigation expense and $14.2M other operating income.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Aortic valve replacement | 1 | $1.2B | TAVR core; 73% of sales; +14% |
| Mitral & tricuspid therapies | 1 | $175M | The next transcatheter platform; +52% |
| Surgical heart valves | 1 | $276M | Established surgical franchise; +10% |
| Structural-heart sales | 2 | $1.6B | +16.7% year over year |
| United States | 3 | $938M | 57% of sales; +12% |
| Europe | 3 | $443M | 27% of sales; +30% |
| Japan | 3 | $90.6M | 5% of sales; +11% |
| Rest of world | 3 | $178M | 11% of sales; +18% |
| Global valve platform | 4 | $1.6B | Catheter-based and surgical treatment |
| Gross profit | 5 | $1.3B | 78.0% gross margin |
| Valve manufacturing & delivery | 5 | $363M | Precision devices and clinical supply chain |
| Operating income | 6 | $478M | 29.0% operating margin |
| Research & development | 6 | $263M | 16.0% of sales |
| Clinical selling, litigation & other | 6 | $545M | Global physician support and corporate costs |
| From | To | Value |
|---|---|---|
| Aortic valve replacement | Structural-heart sales | $1.2B |
| Mitral & tricuspid therapies | Structural-heart sales | $175M |
| Surgical heart valves | Structural-heart sales | $276M |
| Structural-heart sales | United States | $938M |
| Structural-heart sales | Europe | $443M |
| Structural-heart sales | Japan | $90.6M |
| Structural-heart sales | Rest of world | $178M |
| United States | Global valve platform | $938M |
| Europe | Global valve platform | $443M |
| Japan | Global valve platform | $90.6M |
| Rest of world | Global valve platform | $178M |
| Global valve platform | Gross profit | $1.3B |
| Global valve platform | Valve manufacturing & delivery | $363M |
| Gross profit | Operating income | $478M |
| Gross profit | Research & development | $263M |
| Gross profit | Clinical selling, litigation & other | $545M |